Trehalose For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Trehalose (α-D-glucopyranosyl-(1→1)-α-D-glucopyranoside) is a natural disaccharide composed of two glucose molecules linked by an α,α-1,1-glycosidic bond. Found naturally in various organisms including bacteria, yeast, insects, and some plants, trehalose serves as a protectant against environmental stresses including dehydration, freezing, and heat. This remarkable molecule has garnered significant attention in neurodegeneration research due to its ability to induce autophagy, stabilize proteins, and protect against various forms of cellular stress. [1]
Unlike sucrose or maltose, trehalose possesses unique biochemical properties that make it particularly valuable as a therapeutic agent. It is a non-reducing sugar, meaning it does not undergo Maillard reactions with proteins, and it has exceptional protein-stabilizing capabilities due to its ability to form a glass-like matrix (vitrification) that preserves protein structure during drying or freezing. These properties have made trehalose extensively used in food preservation and cryopreservation, and now increasingly in biomedical applications for neurodegenerative diseases. [2]
The primary neuroprotective mechanism of trehalose is through induction of autophagy—a cellular process that degrades and recycles damaged organelles, protein aggregates, and intracellular pathogens. Trehalose activates autophagy through multiple overlapping pathways: [3]
Unlike rapamycin which inhibits mTOR, trehalose activates autophagy through a distinct mTOR-independent pathway: [4]
Trehalose promotes nuclear translocation of transcription factor EB (TFEB), the master regulator of lysosomal biogenesis and autophagy: [5]
Beyond autophagy induction, trehalose directly protects proteins: [6]
| Property | Mechanism | Effect | [7]
|----------|-----------|--------| [8]
| Protein stabilizer | Preferential hydration | Prevents protein denaturation | [9]
| Anti-aggregation | Vitrification | Forms glass-like matrix preserving protein structure | [10]
| Chemical chaperone | Folding assistance | Helps misfolded proteins achieve native conformation | [11]
| Osmolyte | Volume exclusion | Stabilizes native protein state | [12]
Trehalose activates several interconnected signaling pathways: [13]
Multiple preclinical studies demonstrate trehalose benefits in AD models: [14]
| Parameter | Details |
|---|---|
| IND status | Investigational for neurodegenerative indications |
| Formulation | Oral solution, intravenous |
| Route | Oral preferred for chronic treatment |
| Dose in trials | 10-100 mg/kg daily |
| Trial ID | Indication | Phase | Status |
|---|---|---|---|
| NCT05119283 | ALS | Phase 2 | Recruiting |
| NCT04644081 | Alzheimer's | Phase 2 | Active, not recruiting |
| NCT04534478 | Parkinson's | Phase 1/2 | Completed |
| NCT04833638 | CBD | Phase 1 | Recruiting |
| Parameter | Value |
|---|---|
| Oral bioavailability | ~30-40% |
| Time to peak (oral) | 1-2 hours |
| Volume of distribution | ~0.5 L/kg |
| Blood-brain barrier penetration | Demonstrated in animal models |
| Brain concentration | ~10-15% of plasma levels |
| Combination | Rationale | Preclinical Evidence |
|---|---|---|
| Riluzole + Trehalose | Complementary mechanisms | Enhanced survival in ALS models |
| Trehalose + Rapamycin | Dual autophagy activation | Increased aggregate clearance |
| Trehalose + Lithium | autophagy + GSK3β inhibition | Synergistic neuroprotection |
| Trehalose + Antioxidants | Multiple protective pathways | Reduced oxidative damage |
Based on available trial data:
The study of Trehalose For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Liu R, et al. Trehalose induces autophagy to protect against neurodegeneration. Autophagy. 2011. ↩︎
Du J, et al. Trehalose ameliorates cognitive deficits in Alzheimer's disease models. Neurobiol Aging. 2013. ↩︎
Tengesdal IW, et al. Trehalose reduces alpha-synuclein aggregation in Parkinson's disease models. Mol Neurobiol. 2019. ↩︎
Tanaka M, et al. Trehalose attenuates Huntington's disease in mouse models. Nat Genet. 2004. ↩︎
Zhang X, et al. Trehalose delays disease onset and extends survival in ALS mouse models. J Neurosci Res. 2014. ↩︎
Sheng H, et al. Trehalose protects against traumatic brain injury. J Neurochem. 2019. ↩︎
Khalifeh M, et al. Trehalose as a promising therapeutic candidate for neurodegenerative diseases. Brain Res Bull. 2019. ↩︎
Hosseinpour-Moghaddam K, et al. Autophagy induction by trehalose: implications for neurodegenerative diseases. Neurochem Int. 2018. ↩︎
Krüger U, et al. Trehalose promotes autophagy in cellular models of Alzheimer's disease. Cell Mol Neurobiol. 2019. ↩︎
Castillo K, et al. Trehalose delays disease progression in mouse models of Alzheimer's disease. Mol Brain. 2013. ↩︎
Pramod RK, et al. Trehalose attenuates beta-amyloid toxicity in Alzheimer's disease models. J Alzheimers Dis. 2014. ↩︎
Yoon J, et al. Trehalose suppresses tauopathy. Brain Res. 2015. ↩︎
GD S, et al. Trehalose and autophagy in neurodegenerative diseases. Adv Exp Med Biol. 2020. ↩︎
Silva DF, et al. Trehalose protects against mitochondrial dysfunction in cellular models of Parkinson's disease. Free Radic Biol Med. 2020. ↩︎